{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:51:18Z","timestamp":1788821478702,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mammary Gland Biol Neoplasia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10911-024-09571-3","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:31:53Z","timestamp":1731047513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Gestational breast cancer: distinctive molecular and clinico-epidemiological features"],"prefix":"10.1007","volume":"29","author":[{"given":"J. R.","family":"de la Haba-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"M\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Servitja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"P\u00e9rez-Fidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gavil\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodriguez-Lescure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Pe\u00f1a-Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hern\u00e1ndez-Blanquisett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guil-Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MT.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Blanch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Poll\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guerrero-Zotano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"issue":"4","key":"9571_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.breast.2012.05.002","volume":"21","author":"A-S Genin","year":"2012","unstructured":"Genin A-S, Lesieur B, Gligorov J, Antoine M, Selleret L, Rouzier R. Pregnancy-associated breast cancers: Do they differ from other breast cancers in young women? The Breast. 2012;21(4):550\u20135.","journal-title":"The Breast"},{"issue":"4","key":"9571_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.diii.2013.12.021","volume":"95","author":"A Langer","year":"2014","unstructured":"Langer A, Mohallem M, Stevens D, Rouzier R, Lerebours F, Ch\u00e9rel P. A single-institution study of 117 pregnancy-associated breast cancers (PABC): Presentation, imaging, clinicopathological data and outcome. Diagn Interv Imaging. 2014;95(4):435\u201341.","journal-title":"Diagn Interv Imaging"},{"key":"9571_CR3","doi-asserted-by":"publisher","first-page":"v266","DOI":"10.1093\/annonc\/mdq198","volume":"21","author":"G Pentheroudakis","year":"2010","unstructured":"Pentheroudakis G, Orecchia R, Hoekstra HJ, Pavlidis N. Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v266\u201373.","journal-title":"Ann Oncol"},{"issue":"4","key":"9571_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrc1839","volume":"6","author":"P Schedin","year":"2006","unstructured":"Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer. 2006;6(4):281\u201391.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"9571_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10549-007-9616-6","volume":"108","author":"A Molckovsky","year":"2008","unstructured":"Molckovsky A, Madarnas Y. Breast cancer in pregnancy: a literature review. Breast Cancer Res Treat. 2008;108(3):333\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"9571_CR6","doi-asserted-by":"publisher","first-page":"154413","DOI":"10.1016\/j.prp.2023.154413","volume":"244","author":"EM Proussaloglou","year":"2023","unstructured":"Proussaloglou EM, Blanco LZ Jr, Siziopikou KP. Updates in the pathology of Pregnancy Associated Breast Cancer (PABC). Pathol Res Pract. 2023;244:154413.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"9571_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.molmed.2013.11.002","volume":"20","author":"F Meier-Abt","year":"2014","unstructured":"Meier-Abt F, Bentires-Alj M. How pregnancy at early age protects against breast cancer. Trends Mol Med. 2014;20(3):143\u201353.","journal-title":"Trends Mol Med"},{"issue":"1","key":"9571_CR8","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1038\/s41467-018-06748-3","volume":"9","author":"A Husby","year":"2018","unstructured":"Husby A, Wohlfahrt J, \u00d8yen N, Melbye M. Pregnancy duration and breast cancer risk. Nat Commun. 2018;9(1):4255.","journal-title":"Nat Commun"},{"issue":"10","key":"9571_CR9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.molmed.2019.06.003","volume":"25","author":"PF Slepicka","year":"2019","unstructured":"Slepicka PF, Cyrill SL, dos Santos CO. Pregnancy and Breast Cancer: Pathways to Understand Risk and Prevention. Trends Mol Med. 2019;25(10):866\u201381.","journal-title":"Trends Mol Med"},{"issue":"5","key":"9571_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/oxfordjournals.aje.a113462","volume":"116","author":"DT Janerich","year":"1982","unstructured":"Janerich DT, Hoff MB. Evidence, for a crossover in breast cancer risk factors1. Am J Epidemiol. 1982;116(5):737\u201342.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"9571_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1245\/s10434-011-2104-6","volume":"19","author":"M Pilewskie","year":"2012","unstructured":"Pilewskie M, Gorodinsky P, Fought A, Hansen N, Bethke K, Jeruss J, Scholtens D, Khan SA. Association between Recency of Last Pregnancy and Biologic Subtype of Breast Cancer. Ann Surg Oncol. 2012;19(4):1167\u201373.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"9571_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s12253-013-9735-9","volume":"20","author":"L Madaras","year":"2014","unstructured":"Madaras L, Kov\u00e1cs KA, Sz\u00e1sz AM, Kenessey I, T\u0151k\u00e9s A-M, Sz\u00e9kely B, Barany\u00e1k Z, Kiss O, Dank M, Kulka J. Clinicopathological Features and Prognosis of Pregnancy Associated Breast Cancer \u2013 A Matched Case Control Study. Pathology & Oncology Research. 2014;20(3):581\u201390.","journal-title":"Pathology & Oncology Research"},{"key":"9571_CR13","first-page":"551","volume":"9","author":"AH Blanquisett","year":"2015","unstructured":"Blanquisett AH, Vicent CH, Gregori JG, Zotano \u00c1G, Porta VG, Sim\u00f3n AR. Breast cancer in pregnancy: an institutional experience. Ecancermedicalscience. 2015;9:551\u2013551.","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"9571_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/ERC-14-0111","volume":"21","author":"HA Azim Jr","year":"2014","unstructured":"Azim HA Jr, Brohee S, Peccatori FA, Desmedt C, Loi S, Lambrechts D, Dell\u2019Orto P, Majjaj S, Jose V, Rotmensz N, et al. Biology of breast cancer during pregnancy using genomic profiling. Endocr Relat Cancer. 2014;21(4):545\u201354.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"9571_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12672-013-0136-z","volume":"4","author":"DME Harvell","year":"2013","unstructured":"Harvell DME, Kim J, O\u2019Brien J, Tan A-C, Borges VF, Schedin P, Jacobsen BM, Horwitz KB. Genomic Signatures of Pregnancy-Associated Breast Cancer Epithelia and Stroma and their Regulation by Estrogens and Progesterone. Hormones and Cancer. 2013;4(3):140\u201353.","journal-title":"Hormones and Cancer"},{"issue":"11","key":"9571_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jnci\/djn151","volume":"100","author":"M Martin","year":"2008","unstructured":"Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodriguez CA, Crespo C, de Alava E, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100(11):805\u201314.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9571_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10549-013-2416-2","volume":"138","author":"M Martin","year":"2013","unstructured":"Martin M, Prat A, Rodriguez-Lescure A, Caballero R, Ebbert MT, Munarriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013;138(2):457\u201366.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"9571_CR18","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-16-2092","volume":"23","author":"A Prat","year":"2017","unstructured":"Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, de la Haba-Rodr\u00edguez J, Arcusa A, Chac\u00f3n JI, S\u00e1nchez-Rovira P, et al. A PAM50-based chemoendocrine score for hormone receptor positive breast cancer with an intermediate risk of relapse. Clin Cancer Res. 2017;23(12):3035\u201344.","journal-title":"Clin Cancer Res."},{"key":"9571_CR19","volume-title":"Cancer research: 2016","author":"R Chica Parrado","year":"2016","unstructured":"Chica Parrado R, Jimenez-Rodriguez B, Sanchez Rovira P, Alvarez M, Vicioso L, Fernandez A, de Luque V, Jose Lozano M, Villar E, Zarcos I. Prosigna subtype correlation is a strong predictor of response to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) study. In: Cancer research: 2016. Philadelphia, PA: Amer Assoc Cancer Research 615 Chestnut St, 17TH floor; 2016."},{"key":"9571_CR20","volume-title":"GEICAM Spanish Breast Cancer Group Madrid","author":"Group GSBC","year":"2014","unstructured":"Group GSBC. Proyecto El \u00c1lamo III. Encuesta de Evoluci\u00f3n de Pacientes Con C\u00e1ncer de Mama en Hospitales del Grupo GEICAM (1998\u20132001). In: GEICAM Spanish Breast Cancer Group Madrid. Spain: GEICAM Spanish Breast Cancer Group Madrid; 2014."},{"issue":"15_suppl","key":"9571_CR21","doi-asserted-by":"publisher","first-page":"e12016","DOI":"10.1200\/jco.2010.28.15_suppl.e12016","volume":"28","author":"C Jara-Sanchez","year":"2010","unstructured":"Jara-Sanchez C, Ruiz A, Martin M, Prado PMd, Santaballa A, Llombart-Cussac A, Batista J, Poll\u00e1n M, Carrasco EM, Lluch A. Spanish Breast Cancer Research Group (GEICAM) hospital-based study on breast cancer outcomes: El \u00c1lamo project (1990\u20132001). J Clin Oncol. 2010;28(15_suppl):e12016.","journal-title":"J Clin Oncol"},{"issue":"9","key":"9571_CR22","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1200\/JCO.2014.57.2388","volume":"33","author":"M Martin","year":"2015","unstructured":"Martin M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Munoz M, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole\/fulvestrant and avastin (LEA) study. J Clin Oncol. 2015;33(9):1045\u201352.","journal-title":"J Clin Oncol"},{"issue":"9","key":"9571_CR23","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-16-2717","volume":"77","author":"JM Cejalvo","year":"2017","unstructured":"Cejalvo JM, Mart\u00ednez de Due\u00f1as E, Galvan P, Garc\u00eda-Recio S, Burgu\u00e9s Gasi\u00f3n O, Par\u00e9 L, Antolin S, Martinello R, Blancas I, Adamo B, et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res. 2017;77(9):2213\u201321.","journal-title":"Cancer Res."},{"issue":"3","key":"9571_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JCO.19.00904","volume":"38","author":"A Lluch","year":"2020","unstructured":"Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano A, Garcia-Saenz JA, Torres R, de la Haba J, et al. Phase III Trial of Adjuvant Capecitabine After Standard Neo-\/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM\/2003-11_CIBOMA\/2004-01). J Clin Oncol. 2020;38(3):203\u201313.","journal-title":"J Clin Oncol"},{"issue":"5","key":"9571_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","volume":"34","author":"AJ van den Broek","year":"2016","unstructured":"van den Broek AJ, Van\u2019t Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, Van Beek M, Janssen-Heijnen ML. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers. J Clin Oncol. 2016;34(5):409\u201318.","journal-title":"J Clin Oncol."},{"issue":"1","key":"9571_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"2","key":"9571_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259\u201371.","journal-title":"Ann Oncol"},{"issue":"9","key":"9571_CR28","first-page":"5116","volume":"98","author":"VG Tusher","year":"2001","unstructured":"Tusher VG, Tibshirani R. Chu GJPotNAoS: Significance analysis of microarrays applied to the ionizing radiation response. 2001;98(9):5116\u201321.","journal-title":"Chu GJPotNAoS: Significance analysis of microarrays applied to the ionizing radiation response"},{"issue":"43","key":"9571_CR29","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"9571_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstr\u00e5le M. Laurila EJNg: PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267\u201373.","journal-title":"Nat Genet."},{"issue":"1","key":"9571_CR31","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.","journal-title":"Nat Commun"},{"key":"9571_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v028.i05","volume":"28","author":"M Kuhn","year":"2008","unstructured":"Kuhn M. Building predictive models in R using the caret package. J Stat Soft. 2008;28:1\u201326.","journal-title":"J Stat Soft."},{"issue":"3","key":"9571_CR33","first-page":"507","volume":"74","author":"JM Rodrigo-Mu\u00f1oz","year":"2019","unstructured":"Rodrigo-Mu\u00f1oz JM, Ca\u00f1as JA, Sastre B, Rego N, Greif G, Rial M, M\u00ednguez P, Mah\u00edllo-Fern\u00e1ndez I, Fern\u00e1ndez-Nieto M, Mora IJA. Asthma diagnosis using integrated analysis of eosinophil microRNAs. 2019;74(3):507\u201317.","journal-title":"Asthma diagnosis using integrated analysis of eosinophil microRNAs"},{"issue":"9","key":"9571_CR34","first-page":"564","volume":"56","author":"S Heili-Frades","year":"2020","unstructured":"Heili-Frades S, Minguez P, Fern\u00e1ndez IM, Hiscock LJ, Santos A, Frades DH. de Miguel MdPC. Ormaechea IF, Su\u00e1rez L\u00c1, Prieto ANJAdB: Patient Management Assisted by a Neural Network Reduces Mortality in an Intermediate Care Unit. 2020;56(9):564\u201370.","journal-title":"Ormaechea IF, Su\u00e1rez L\u00c1, Prieto ANJAdB: Patient Management Assisted by a Neural Network Reduces Mortality in an Intermediate Care Unit"},{"key":"9571_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.canlet.2020.06.005","volume":"494","author":"H Yin","year":"2020","unstructured":"Yin H, Wang X, Zhang X, Zeng Y, Xu Q, Wang W, Zhou F, Zhou YJCL. UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation. Cancer Lett. 2020;494:121\u201331.","journal-title":"Cancer Lett."},{"issue":"20","key":"9571_CR36","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1158\/0008-5472.CAN-18-0273","volume":"78","author":"R Bayley","year":"2018","unstructured":"Bayley R, Blakemore D, Cancian L, Dumon S, Volpe G, Ward C, Almaghrabi R, Gujar J, Reeve N. Raghavan MJCr: MYBL2 supports DNA double strand break repair in hematopoietic stem cells. Cancer Res. 2018;78(20):5767\u201379.","journal-title":"Cancer Res."},{"issue":"1","key":"9571_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17836-7","volume":"7","author":"J Perez-Pe\u00f1a","year":"2017","unstructured":"Perez-Pe\u00f1a J, Corrales-S\u00e1nchez V, Amir E, Pandiella A. Ocana AJSr: Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Sci Rep. 2017;7(1):1\u20138.","journal-title":"Sci Rep."},{"issue":"9","key":"9571_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0147-0272(83)80006-3","volume":"7","author":"MK Wallack","year":"1983","unstructured":"Wallack MK, Wolf JA Jr, Bedwinek J, Denes AE, Glasgow G, Kumar B, Meyer JS, Rigg LA, Wilson-Krechel S. Gestational carcinoma of the female breast. Curr Probl Cancer. 1983;7(9):1\u201358.","journal-title":"Curr Probl Cancer"},{"issue":"3","key":"9571_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/ijgc-2020-002072","volume":"31","author":"H Lefrere","year":"2021","unstructured":"Lefrere H, Lenaerts L, Borges VF, Schedin P, Neven P, Amant F. Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation. Int J Gynecol Cancer. 2021;31(3):412\u201322.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"9571_CR40","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10549-021-06130-w","volume":"186","author":"BBM Suelmann","year":"2021","unstructured":"Suelmann BBM, van Dooijeweert C, van der Wall E, Linn S, van Diest PJ. Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile. Breast Cancer Res Treat. 2021;186(3):699\u2013704.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"9571_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/ERC-14-0111","volume":"21","author":"HA Azim Jr","year":"2014","unstructured":"Azim HA Jr, Broh\u00e9e S, Peccatori FA, Desmedt C, Loi S, Lambrechts D, Dell\u2019Orto P, Majjaj S, Jose V, Rotmensz N, et al. Biology of breast cancer during pregnancy using genomic profiling. Endocr Relat Cancer. 2014;21(4):545\u201354.","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"9571_CR42","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<720::AID-IJC3>3.0.CO;2-U","volume":"72","author":"P Bonnier","year":"1997","unstructured":"Bonnier P, Romai S, Dilhuydy JM, Bonichon F, Julien JP, Charpin C, Lejeune C, Martin PM, Piana L. Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer. 1997;72(5):720\u20137.","journal-title":"Int J Cancer"},{"issue":"1","key":"9571_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng0995-17","volume":"11","author":"ST Marquis","year":"1995","unstructured":"Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin G-Y, Abel KJ, Weber BL. Chodosh LAJNg: The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet. 1995;11(1):17\u201326.","journal-title":"Nat Genet."},{"issue":"9137","key":"9571_CR44","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(05)60750-7","volume":"352","author":"O Johannsson","year":"1998","unstructured":"Johannsson O, Loman KJTL. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet. 1998;352(9137):1359\u201360.","journal-title":"Lancet."},{"issue":"4","key":"9571_CR45","first-page":"699","volume":"22","author":"K-A Phillips","year":"2004","unstructured":"Phillips K-A, Milne RL, Friedlander ML, Jenkins MA, McCredie MR, Giles GG. Hopper JLJJoco: Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. 2004;22(4):699\u2013705.","journal-title":"Hopper JLJJoco: Prognosis of premenopausal breast cancer and childbirth prior to diagnosis"},{"issue":"3","key":"9571_CR46","first-page":"163","volume":"95","author":"SY Bae","year":"2018","unstructured":"Bae SY, Jung SP, Jung ES, Park SM, Lee SK, Yu JH, Lee JE, Kim SW, Nam SJJO. Clinical characteristics and prognosis of pregnancy-associated breast cancer: poor survival of luminal B subtype. 2018;95(3):163\u20139.","journal-title":"Clinical characteristics and prognosis of pregnancy-associated breast cancer: poor survival of luminal B subtype"},{"key":"9571_CR47","first-page":"520","volume-title":"Mayo Clinic Proceedings","author":"EAL Enninga","year":"2014","unstructured":"Enninga EAL, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, Markovic SN. Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. In: Mayo Clinic Proceedings. Elsevier; 2014. p. 520\u201335."},{"issue":"4","key":"9571_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/humupd\/dmg026","volume":"9","author":"A Veenstra van Nieuwenhoven","year":"2003","unstructured":"Veenstra van Nieuwenhoven A, Heineman M, Faas M. The immunology of successful pregnancy. Human Reprod Update. 2003;9(4):347\u201357.","journal-title":"Human Reprod Update."},{"issue":"3","key":"9571_CR49","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.breast.2015.01.009","volume":"24","author":"HA Azim Jr","year":"2015","unstructured":"Azim HA Jr, Vingiani A, Peccatori F, Viale G, Loi S, Pruneri GJTB. Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. Breast. 2015;24(3):290\u20133.","journal-title":"Breast."},{"issue":"2","key":"9571_CR50","first-page":"213","volume":"19","author":"J Fornetti","year":"2014","unstructured":"Fornetti J, Martinson HA, Betts CB, Lyons TR, Jindal S, Guo Q, Coussens LM. Borges VF. Schedin PJJomgb, neoplasia: Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. 2014;19(2):213\u201328.","journal-title":"Schedin PJJomgb, neoplasia: Mammary gland involution as an immunotherapeutic target for postpartum breast cancer"},{"issue":"2","key":"9571_CR51","first-page":"608","volume":"168","author":"SM McDaniel","year":"2006","unstructured":"McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W. Schedin PJTAjop: Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. 2006;168(2):608\u201320.","journal-title":"Schedin PJTAjop: Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis"},{"issue":"2","key":"9571_CR52","first-page":"1","volume":"6","author":"T Stein","year":"2004","unstructured":"Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy M-A, Heath VJ, Bell AK, Ferrier RK, Sandilands GP, Gusterson BA. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res. 2004;6(2):1\u201317.","journal-title":"Breast Cancer Res."},{"issue":"9","key":"9571_CR53","first-page":"9","volume":"80","author":"VFBTRLDGP Schedin","year":"2020","unstructured":"Schedin VFBTRLDGP. Postpartum involution and cancer: an opportunity for targeted breast cancer prevention and treatments? Cancer Res. 2020;80(9):9.","journal-title":"Cancer Res."},{"issue":"2","key":"9571_CR54","doi-asserted-by":"publisher","first-page":"188407","DOI":"10.1016\/j.bbcan.2020.188407","volume":"1874","author":"R Bayley","year":"2020","unstructured":"Bayley R, Ward C, Garcia P. MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188407.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"4","key":"9571_CR55","doi-asserted-by":"publisher","first-page":"zcac035","DOI":"10.1093\/narcan\/zcac035","volume":"4","author":"R Dutta","year":"2022","unstructured":"Dutta R, Guruvaiah P, Reddi KK, Bugide S, Reddy Bandi DS, Edwards YJK, Singh K, Gupta R. UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress. NAR Cancer. 2022;4(4):zcac035.","journal-title":"NAR Cancer."}],"container-title":["Journal of Mammary Gland Biology and Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10911-024-09571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10911-024-09571-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10911-024-09571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T08:06:12Z","timestamp":1731053172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10911-024-09571-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9571"],"URL":"https:\/\/doi.org\/10.1007\/s10911-024-09571-3","relation":{},"ISSN":["1083-3021","1573-7039"],"issn-type":[{"value":"1083-3021","type":"print"},{"value":"1573-7039","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"27 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the applicable Clinical Research Ethics Committees of the participating Spanish clinical sites (Supplementary Table\u00a06). Study procedures were conducted in accordance with the Declaration of Helsinki, as revised in 2013, and good clinical practice guidelines. Informed consent was obtained for the collection of local epidemiological, clinico-pathological, and biological data, and biomarker assessment according to applicable legislation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J. de la Haba-Rodriguez declares having received research grants from Roche and Pfizer, consulting\/advisory fees from AstraZeneca, Amgen, Roche\/Genentech, Novartis, Eli Lilly and Pfizer and speakers\u2019 honoraria from AstraZeneca, Lilly, Amgen, Roche\/Genentech, Novartis, and Pfizer, but declares no non-financial competing interests. A. Prat declares stock and Other Ownership Interests from Reveal Genomics; honoraria from Pfizer, Novartis, Roche, MSD Oncology, Lilly, Daiichi Sankyo, Amgen, and Guardant Health; consulting\/advisory role from Amgen, Roche, Novartis, Pfizer, Bristol-Myers Squibb, Boehringer, PUMA, Oncolytics Biotech., Daiichi Sankyo, Abbvie, AstraZeneca, and NanoString Technologies; research funding from Roche, Novartis, Incyte, and Puma Biotechnology; travel \/accommodation expenses from Daiichi Sankyo. Other relationship with companies as, Oncolytics, and Peptomyc S.L.; stock at Reveal Genomics; and patents\/royalties from PCT\/EP2016\/080056, WO\/2018\/096191, HER2DX filing, and US 63\/023785, but declares no non-financial competing interests. A. Guerrero-Zotano declares institutional grant from Pfizer; advisory role honoraria from Novartis, Palex, Pfizer, AstraZeneca and Pierre Fabre; travel grants from Roche, Pfizer, and Novartis, but declares no non-financial competing interests. M. Martin declares having received research grants from Roche, PUMA and Novartis, consulting\/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche\/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi Sankyo and Pfizer and speakers\u2019 honoraria from AstraZeneca, Lilly, Amgen, Roche\/Genentech, Novartis, and Pfizer, but declares no non-financial competing interests. F. Rojo declares research grants from Roche, consulting\/advisory fees from BMS, MSD, AstraZeneca, Janssen, Roche\/Genentech, Novartis, Eli Lilly, and Daiichi Sankyo, but declares no non-financial competing interests. J.A. Perez-Fidalgo declares research grants from Pharmamar, Novartis and GSK consulting\/advisory fees from AstraZeneca, Amgen, Abilify Pharma, GSK Tesaro, Pharmamar and Clovis and speakers\u2019 honoraria from AstraZeneca, GSK Tesaro, Pharmamar, Roche, Clovis, and Pfizer. Co-inventorship of a European patent of response prediction in triple negative breast cancer, but declares no non-financial competing interests. J. Gavila declares having received advisory role honoraria from Novartis Pfizer, AstraZeneca; travel grants from Roche, Pfizer, and Novartis, but declares no non-financial competing interests. All other authors declare no financial or non-financial competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}